Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the approved product's label, the FDA's compounding rules and the structure of US drug pricing, and they change on timescales of months.
Bremelanotide has a list price, a prescription route, a manufacturer and, for premenopausal women with a diagnosed desire disorder, a possible insurance pathway. It is also, in the market that actually uses the name PT-141, bought by men, for whom none of that applies.1
This page publishes no prices. What follows is what determines the money.
How Bremelanotide Pricing Works
Why There Is No Single Price
Vyleesi is a branded specialty product sold as single-dose autoinjectors in packs of two or four, priced per dose, with a manufacturer list price at the top of the usual stack of discounts and support programmes.1 The woman with coverage for the approved indication pays a copay. The woman paying cash pays a per-dose figure that the manufacturer's savings programme may reduce. The man paying a clinic pays for compounded product and a consultation. The person buying a research vial pays a vendor for a powder that may or may not be bremelanotide.
Those are four prices for four things, and the last two are not for the approved product.
What Is Actually Being Priced?
A dose, taken as needed, no more than once in 24 hours and no more than eight times a month.1 That makes bremelanotide, unusually for this library, a per-event cost rather than a monthly one. It also makes the dose ceiling a cost ceiling: the label caps what can be spent in a month by capping what can be taken, and the gray market removes both caps together.
Insurance
Coverage Depends on the Indication, Not the Molecule
Vyleesi is approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder not due to a medical or psychiatric condition, a relationship problem or a drug.1 Where plans cover it, that is the indication, typically with prior authorisation documenting the diagnosis and, often, a trial of flibanserin first. Coverage is patchy; many plans exclude sexual dysfunction drugs as a class, and the manufacturer's copay programme exists because of that.
For men, for postmenopausal women, and for anyone without the diagnosis, there is no covered indication and nothing to appeal. The label states the drug is not indicated for those uses, and a denial on that basis is correct on the plan's own terms.
Can HSA or FSA Funds Be Used?
For a prescription for the approved product, on the ordinary basis that it is a prescribed medicine, generally yes, including off-label. For compounded product from a pharmacy with a prescription, generally the same. For research vials, no: there is no prescription and no medical expense, and the account holder carries the consequences.
Off-Label Access
Can a Doctor Prescribe It for a Man?
Yes, off-label, which is lawful and common. What changes is the evidence and the money. The evidence for men is two intranasal trials from 2004 and 2008, by a route not sold, at doses that do not correspond to the injection.23 The money becomes cash-pay at whatever the channel charges, and the label's cardiovascular screening and dose limits do not switch off because the patient is not the one on the label.1
Why Is Compounded Bremelanotide Cheaper?
Because it is not the same product and, for the approved population, is not permitted to be sold as if it were. Bremelanotide can be compounded because it is a component of an approved drug, but not as "essentially a copy" of the commercial product; the FDA's guidance says a lower price is not a qualifying difference.4 A compounded vial skips the autoinjector, the manufacturing standard, the stability data and the label, and the discount is the sum of what it skips.
For men, the compounded product is not a copy of anything, because nothing is approved for them, and its price is a price for off-label use of a compounded version of a drug labelled to exclude them.
What the Money Buys
Where Does the Spread Between Channels Come From?
| Channel | What is supplied | What the price includes | What it does not |
|---|---|---|---|
| Specialty pharmacy, on-label, insured | Vyleesi autoinjector | Verified product, label, a fixed dose, cardiovascular screening under a prescriber, plan negotiation | Anything off-label |
| Specialty pharmacy, cash | Vyleesi autoinjector | Verified product and label; manufacturer savings programme where eligible | Coverage |
| Compounding pharmacy or men's-health telehealth | Compounded bremelanotide, usually a multi-dose vial | A prescription and a pharmacy label; a consultation | The fixed dose; the manufacturing standard; for women, legal standing under the copy rule; for men, any trial by this route |
| Research vendor | Powder labelled PT-141 | A vial | Identity, a prescription, a label, cardiovascular screening, any distinction from melanotan II |
ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown. Each step down the table removes something. The last row removes the certainty that the peptide is bremelanotide rather than its parent, which differs by one dalton and carries a melanoma and priapism record.5
Why Is the Vial Cheaper Per Dose?
A 10 mg research vial holds roughly six labelled doses, and per milligram it costs a fraction of the autoinjector. It is cheaper because it is not sterile-filled into a device, not dose-controlled, not labelled, and not necessarily bremelanotide. The autoinjector is expensive partly because it makes the labelled dose the only dose available, which is the drug's safety case in physical form.1 A buyer who prices the vial against the device is pricing the absence of that.
The Spending Decision
What Result Is Being Paid For?
On-label: a 0.35-point increase in a desire score over placebo on a 1.2-to-6 scale, and a 0.33-point reduction in distress, over 24 weeks, in premenopausal women with a diagnosed disorder, at the cost of nausea in 40 percent.61 That is a real, reproduced, modest effect, and whether it is worth its price is a judgement the approval left to patients and prescribers.
Off-label in men: an erectile response in early intranasal trials, including in a third of sildenafil non-responders, by a route and at doses that do not match the product sold.3 For the injection in men, nothing has been measured. For "libido enhancement" in anyone without a disorder, the label says the drug is not indicated, and no trial has tested it.
A man buying PT-141 is paying for a women's drug on the strength of men's trials of a different formulation, delivered by a route with no data in him, at doses above a limit set for blood pressure reasons. The approval is real. It is somebody else's.
Is It Cheaper Than the Alternatives?
For erectile dysfunction, the comparison is with sildenafil and tadalafil, which are generic, cheap, approved for men, and act on blood flow rather than the brain. Bremelanotide's case in men was always as a salvage or add-on for those who do not respond to them.3 A man who has not tried the approved drugs is paying more for less evidence.
What Should Be Asked Before Paying?
Is this Vyleesi, compounded bremelanotide, or a research vial? The answer determines everything else.
Has my blood pressure been measured, and do you know the drug is contraindicated in uncontrolled hypertension and cardiovascular disease?1
Which trial tested this route and dose in someone like me?
For a vial, does the certificate report an observed mass that distinguishes bremelanotide from melanotan II?
What is the plan if pigmentation develops, which the label says may not resolve?
Does anyone here earn commission on product sales?
What Would Change This Page
A Men's Approval, a Generic, or a Coverage Change
A controlled trial of subcutaneous bremelanotide in men, followed by a filing, would create an on-label route for the population that actually buys it; no sponsor has registered one. Generic entry would change the cash-pay position for the approved product; none is approved. Broader coverage of sexual dysfunction drugs would change access for women with the diagnosis; that is a policy question, not a pharmacology one.
A Note on Price Comparisons
Figures circulate comparing PT-141 vials favourably with Vyleesi per dose. The comparison is between a product with a fixed dose, a label and a verified identity and one with none of those, for a buyer the label excludes. ONPEPS does not make it.
Related ONPEPS Coverage
PT-141 library entry: the trials, the label and the off-label market
PT-141 sourcing and quality: the approved autoinjector and the vial next to the melanotan
Tesamorelin cost and access: a specialty drug with one indication
Sources
Cosette Pharmaceuticals, Inc. VYLEESI (bremelanotide) injection: prescribing information. Revised March 2024. DailyMed. dailymed.nlm.nih.gov
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. Paywalled. pubmed.ncbi.nlm.nih.gov/14963471
Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-1071. Paywalled. pubmed.ncbi.nlm.nih.gov/18206919
US Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. January 2018. fda.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for Melanotan II. Content current as of 22 April 2026. fda.gov
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. Open access. pubmed.ncbi.nlm.nih.gov/31599840
Not Medical or Financial Advice
Bremelanotide is a prescription medicine, and treatment decisions belong with a prescriber who has read its label. Coverage decisions belong with the plan. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what determines what the money would be spent on.
Sources verified 16 September 2026. Pricing, coverage criteria and manufacturer support programmes change frequently. Re-verify before relying on anything here.